Regeneron (REGN) Q3 2026 earnings review
Regeneron's Sanofi profits jump, while its US eye sales recover
Regeneron's profit share from partner Sanofi jumped while its US eye-disease business grew from last quarter. Total revenue rose 36% to $5.1 billion, and profit per share excluding one-offs climbed 70% after finance chief Christopher Fenimore noted the company finished paying back past Sanofi research costs. Chief executive Leonard S. Schleifer highlighted record sales for Dupixent, EYLEA HD, and cancer drug Libtayo, and the company raised its full-year product gross margin outlook above what its prior plan pointed to.
| Revenue | $5,116M +36% from a year ago |
|---|---|
| Profit per share, excluding one-offs | $20.07 +70% from a year ago |
| Sanofi collaboration revenue | $2,724M +68% from a year ago |
| Full-year product gross margin outlook, excluding one-offs | Raised to ~86% from 84%–85% previously |
⚖️ Verdict: 🟢 Bullish
The story got better because the high-dose EYLEA HD switch lifted total US eye sales by 9% from last quarter, while a new $1 billion Sanofi antibody deal eased fears over their legal dispute. Beating the implied second-half gross margin target also shows the earlier margin plan was cautious once the Limerick factory returned to normal. One caution: overseas eye-drug profits fell 32% by our math, and lower US selling prices are still not quantified.
The question now is whether EYLEA HD can keep growing total US eye sales as cheaper copycats of original EYLEA launch and press on prices. Either the high-dose medicine holds prices and grows the franchise, or unquantified discounts pull combined revenue back down. Fourth-quarter US eye sales and the year-end pre-filled syringe decision will tell.
🐂 Bull Case
Sanofi Profit Share Steps Up and Expands
Regeneron shares profits with French drugmaker Sanofi on Dupixent, an injection for eczema and asthma, and Kevzara, an arthritis medicine. Critics note this single partnership now supplies over half of total revenue and carries legal disputes over audit rights. Finance chief Christopher Fenimore pointed to the "anticipated step-up in Sanofi collaboration revenue in the first full quarter following repayment of the Development Balance".
- Sanofi collaboration revenue: $2.72 billion, up 68% from a year ago and up 25% from last quarter
- Antibody profit share: $2.57 billion, or 37.9% of partner drug sales, up from 32.8% last quarter by our math
- Dupixent global sales recorded by Sanofi: $6.54 billion, up 35% from a year ago
- New Sanofi deal: $1.0 billion up-front in the fourth quarter, plus up to $7.0 billion in milestones
The jump happened because Regeneron finished paying back past research costs in June, so it now keeps its full profit share. In October, the two companies also added four antibodies "designed to build on the success of Dupixent" to their alliance, easing fears of a rift.
What to watch: fourth-quarter Sanofi collaboration revenue excluding the $1.0 billion up-front payment. A profit-share rate holding near 38% of partner sales would confirm the higher cash flow baseline.
EYLEA HD Lifts US Eye Drug Sales
EYLEA is an injection for serious eye diseases, and EYLEA HD is the newer high-dose version that lets patients go longer between clinic visits. "This was an outstanding quarter for Regeneron, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales," chief executive Leonard S. Schleifer said. The company wants patients to switch to EYLEA HD before cheaper copycats of original EYLEA take over.
- EYLEA HD US sales: $699 million, up 62% from a year ago and up 17.2% from last quarter by our math
- Original EYLEA US sales: $400 million, down 41% from a year ago and down 3.0% from last quarter by our math
- Combined US eye franchise: $1.10 billion, up 8.9% from last quarter and down 1% from a year ago
Both drugs beat the sequential demand outlook management gave three months ago. Because EYLEA HD now makes up 64% of US eye sales by our math, its gains outweighed the older drug's decline and grew the combined US franchise from last quarter.
What to watch: fourth-quarter US EYLEA and EYLEA HD sales as new 2 mg copycat versions launch. Holding combined US sales near $1.1 billion would show the high-dose switch can absorb copycat competition.
Product Gross Margin Beat a Cautious Plan
Gross margin on net product sales measures the profit left from Regeneron's own drug sales after cost of goods sold, the cost of making the medicines. Earlier this year, repairs at a bulk plant in Limerick, Ireland added $161 million of idle factory costs. Three months ago, the full-year outlook pointed by our math to a second-half margin excluding one-offs of 82% to 84%.
Instead, third-quarter product gross margin reached 82% on a reported basis and 86% excluding one-offs, as Limerick interruption charges dropped to zero. That beat shows the earlier outlook was cautious, so the biotech group raised its full-year margin forecast on both bases. Reported operating margin also rose 12.7 percentage points from a year ago by our math, as selling and overhead costs fell 4.3 points of revenue.
What to watch: fourth-quarter cost of goods sold as a share of product sales. A reported product gross margin near 83%, implied by the full-year outlook, would confirm normal factory operations.
Libtayo and Rare-Disease Approvals Broaden Sales
Regeneron sells Libtayo, an immunotherapy for skin and lung cancers, and is advancing roughly 50 experimental medicines to rely less on eye and allergy drugs. Global Libtayo sales jumped 51% from a year ago to $550 million, led by an 81% rise in the United States to $396 million after winning approval last year for high-risk skin cancer after surgery.
The clinical pipeline also turned science into approved products. In August, US regulators approved Pasatru, an antibody for a rare disease that turns muscle into bone, and Japanese regulators approved Libtayo for skin cancer. Because new rare-disease drugs ramp slowly — blood-cancer drug Lynozyfic reached $19 million this quarter — these approvals add long-term breadth rather than immediate revenue.
What to watch: the US regulatory decision in November 2026 on cemdisiran for generalized myasthenia gravis, a nerve and muscle disorder. Approval would open a larger commercial market in 2027.
🐻 Bear Case
Eye Drug Prices and Overseas Profits Shrink
Schleifer highlighted record sales for EYLEA HD, and US revenue for the eye franchise stabilized sequentially. Yet the company said EYLEA HD volume gains were "partly offset by a lower net selling price", while original EYLEA suffered from "continued competitive pressures and the continued transition of patients to EYLEA HD". Outside the United States, partner Bayer sells both eye drugs and splits the profit.
- Global EYLEA and EYLEA HD sales: $1.74 billion, down 11% from a year ago
- Overseas original EYLEA sales recorded by Bayer: $259 million, down 58% from a year ago by our math
- Regeneron share of Bayer eye profits: $212 million, down 32% from a year ago by our math
This cuts against the record-sales headline because global eye revenue is still falling and management never discloses how much it cuts prices to win volume. Without the price figure, investors cannot tell where revenue settles once copycats arrive in force.
What to watch: Bayer collaboration profit share and any price commentary on the conference call. A steeper drop in fourth-quarterUS or overseas eye revenue would show price discounts are accelerating.
Research Spending Rises Above the Prior Plan
Regeneron invests heavily in research and development (R&D), the cost of running laboratory studies and clinical trials, to fund its 50 drug candidates. Some investors have questioned whether this multi-billion-dollar budget turns into commercial drugs fast enough after a skin-cancer combination trial failed earlier this year.
In the third quarter, reported R&D spending rose 22% from a year ago to $1.79 billion, or 23% to $1.65 billion excluding one-offs. Management raised its full-year R&D spending forecast by $100 million on both bases, citing clinical pipeline advancement and manufacturing for experimental drugs. Although faster revenue growth lowered R&D as a share of revenue by 4.2 percentage points to 35.1% by our math, the dollar commitment keeps climbing.
What to watch: fourth-quarter R&D spending against the implied $1.70 billion reported target by our math, alongside late-stage trial readouts. Missed clinical endpoints would renew pressure on the rising research budget.
Risks this quarter didn't answer
Four standing concerns from prior quarters got no new details in the third-quarter press release and depend on the conference call or quarterly filing.
- EYLEA HD pre-filled syringe: no update on the US regulatory review after five quarters of contractor delays; year-end 2026 remains the test.
- Fourth-quarter clinical readouts: no update on late-stage blood-disorder (PNH) and eye (geographic atrophy) data due by year-end.
- In-house filling plant: no timeline update on internal syringe filling capacity meant to reduce reliance on outside factories.
- Legal proceedings: no update in the release on Justice Department pricing probes, shareholder suits, or Dupixent liability claims; the 10-Q filing will carry the legal note.
👓 Other Themes
Medicaid Pricing Deal Trades Discounts for Tariff Relief
In April 2026, Regeneron signed an agreement with the US government to supply medicines to Medicaid at Most-Favored-Nation prices, matching lower rates paid in other wealthy countries. In exchange, the drugmaker receives three years of tariff relief and protection from future federal pricing mandates while building US factories. The release notes this policy in its risk disclosures but does not break out its dollar effect on sales.
💲 Other KPIs
Money owed by customers and partners rose 33.3% from a year ago and 15.4% from last quarter by our math, roughly matching the 36.3% jump in total revenue. The $1.84 billion increase since December reflects higher Sanofi profit-share billings and holds back operating cash flow until collected.
Cash received from partners for work not yet completed grew 26.8% from a year ago by our math, adding $64.8 million this quarter after adding $43.9 million in the second quarter. It will jump again in the fourth quarter when Regeneron books the $1.0 billion Sanofi up-front payment.
By our math, third-quarter cash left after factory spending rose 4.7% from a year ago, reversing an 18.4% first-half drop and reaching 29.0% of revenue. Nine-month free cash flow of $2.90 billion still trails last year's $3.16 billion because working capital tied up in receivables and higher factory spending weighed on the first half.
Reported diluted shares fell 1.5% from a year ago and 0.4% from last quarter by our math. The biotech company slowed its buybacks to $300 million in the third quarter by our math, down from $1.2 billion in the second quarter, leaving $2.2 billion authorized.
🔮 Guidance
Raised. Both ends of the reported research budget moved up by $100 million, putting the middle of the range at $6.67 billion, or 14.0% above last year by our math. By our math, that leaves $1.70 billion for the fourth quarter, up 4.4% from a year ago as last year's fourth quarter carried a $155 million voucher charge.
Raised. The plan excluding stock compensation rose $100 million at the middle of the range to $6.10 billion after holding at $6.00 billion for three quarters. By our math, that leaves $1.54 billion for the fourth quarter, down from $1.65 billion in the third quarter.
Cut. The company lowered its reported selling and overhead forecast by $100 million to a middle of $2.80 billion, up 3.5% for the year by our math. It is the second straight cut: -$55 million in Q2, then -$100 million in Q3. By our math, that leaves $807 million for the fourth quarter, up 4.2% from a year ago.
Cut. Management reduced the range by $100 million after trimming the top end by $50 million last quarter. By our math, the $2.45 billion middle leaves $728 million for the fourth quarter, reflecting normal year-end commercial spending.
Raised. The outlook moved up by 1.5 percentage points from the prior middle, restoring the 79.5% target set before the Limerick plant repairs. With the first nine months at 79%, the plan points by our math to about 83% in the fourth quarter.
Raised. It is the second raise this year: +1.0 point in Q2, then +1.5 points in Q3. Because the first nine months already ran at 86%, the updated plan points by our math to 86% in the fourth quarter, removing the second-half drop implied by the prior outlook.
Unchanged. The middle of the range stays at $1.01 billion. With $764 million spent in the first nine months, the plan leaves $246 million for the fourth quarter by our math, down 7.4% from a year ago.
Unchanged. The middle of the range remains $995 million, which excludes $14.8 million of first-quarter Limerick charges. By our math, that leaves $246 million for the fourth quarter, matching the reported figure.
Raised. The company lifted the bottom of the factory budget by $20 million after two cuts earlier in the year (-$50 million in Q1, -$85 million in Q2 at the middle). By our math, the $1.075 billion middle is up 19.7% from 2025 and leaves $304 million for the fourth quarter.
Raised. The forecast moved to the top of the prior range, up 0.5 percentage points from the prior middle. With the nine-month rate at 14.4%, the plan points to a fourth-quarter tax rate just below 13%.
Raised. The outlook moved to the top of the prior range, up 0.5 points from the prior middle, matching the 14.9% rate recorded across the first nine months.
❓ Key Questions
How much did lower prices cut into EYLEA HD sales?
The release again noted that lower net selling prices partly offset EYLEA HD volume growth, while combined US eye sales rose 8.9% sequentially. Without the price vs volume split, investors cannot model how new 2 mg copycats will affect franchise revenue.
Where does the EYLEA HD pre-filled syringe review stand?
Management previously targeted US approval for the pre-filled syringe before the end of 2026 after five quarters of contractor manufacturing delays, but the third-quarter release did not mention the application.
Will fourth-quarter PNH and geographic atrophy trials read out on time?
Last quarter, executives promised late-stage data in paroxysmal nocturnal hemoglobinuria (a rare blood disease) and exploratory data in geographic atrophy (an eye disease) in the fourth quarter, neither of which appeared in today's pipeline update.
Does the new Sanofi deal resolve the audit lawsuit?
Regeneron expanded its antibody alliance with Sanofi for $1.0 billion up-front while previously suing the French partner over audit and information rights. Investors need to know if the October amendment settled the legal dispute.